ET, a chronic myeloproliferative neoplasm (MPN), is characterized by overproduction of platelets, often linked to mutations ...
NEW HAVEN, Conn., Oct. 08, 2024 (GLOBE NEWSWIRE) -- Specialty cancer diagnostics company Precipio, Inc. (PRPO) (NASDAQ: PRPO) announces the launch of a new version of its Bloodhound MPN ...
Multi-hit TP53 mutations are linked to poor survival in both MPN and AML, with median OS ranging from 4.8 to 11.6 months. Factors such as ASCT, pre-transplant therapy response, and concurrent TET2 or ...
Physician-patient communication and shared decision-making approaches in myeloproliferative neoplasm care. This is an ASCO Meeting Abstract from the 2025 ASCO Annual Meeting I. This abstract does not ...
A study reveals that azacitidine, especially in combination with ruxolitinib, improves survival in patients with advanced ...
A subset of patients with myeloproliferative neoplasms (MPNs) -- clonal disorders of hematopoietic stem cells that include polycythemia vera and essential thrombocythemia, as well as primary ...
BOZEMAN, MONTANA, USA, February 1, 2024 /EINPresswire.com/ -- Alercell, Inc., an innovative leader in molecular diagnostics, has recently unveiled its latest ...
Chronic myeloid leukaemia (CML) is a paradigmatic clonal disorder primarily driven by the BCR-ABL translocation, which produces a constitutively active tyrosine kinase. Traditionally, this genetic ...
This transcript has been edited for clarity. For more episodes, download the Medscape app or subscribe to the podcast on Apple Podcasts, Spotify, or your preferred podcast provider. Jain: Wonderful.
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback